Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Currencies, stocks fall on vaccine efficacy worries

11/30/2021 | 04:29am EST

* Moderna CEO warns COVID-19 jabs less effective against Omicron

* MSCI EM stocks index set for monthly decline of 4%

* Turkey's lira falls for third straight session

Nov 30 (Reuters) - Most emerging market currencies dipped on Tuesday on doubts over how effective COVID-19 vaccines are against the Omicron variant, while a gauge for stocks in the developing world was set for its biggest monthly decline in two months.

U.S. drugmaker Moderna's chief, Stéphane Bancel, warned that COVID-19 vaccines were unlikely to be as effective against the Omicron variant of the coronavirus as they have been against the Delta version.

The MSCI's index for emerging market stocks fell 0.4%, set for monthly declines of 4%.

"This is not really new news relative to the last 3-4 days given what we know about the new mutation but the market is picking up on the explicit comments," said Deutsche Bank strategist Jim Reid.

"In reality, the evidence is still incredibly limited on this question, and nothing from the Moderna CEO overnight changes that."

The warning comes a day after global financial markets started the week on firm footing, with analysts pointing to the new variant as a cause for central banks to rein in recent tightening of monetary policy.

Currencies in Asia gave back early gains, while units in Europe, Middle East and Africa were trading flat to lower by 0919 GMT. The drop in developing world currencies was also contained by a weaker U.S. dollar.

South Africa's rand dipped 0.1%, while stocks in the region logged the smallest declines among peers on higher gold prices.

Russia's rouble fell 0.4%, with sliding oil prices to blame. The Russian central bank said it will pursue monetary policy that will bring inflation back to its 4% target by the end of 2022.


Turkey's lira fell in volatile trading for the third day in a row, amid a very low interest rate environment. Turkish President Tayyip Erdogan pledged on Monday to never defend interest rate hikes nor compromise on the issue.

Erdogan's tough stance on keeping interest rates low and influence over the country's central bank has pushed the lira to all-time lows, with the currency losing over 42% this year.

"What has been more interesting over the past couple of days is that the central bank and regulators have begun to intervene in various ways, targeting market participants with short lira positions," said Tatha Ghose, FX and EM analyst at Commerzbank.

"This shows that the authorities are not really comfortable with lira depreciation no matter how much they say that they want a weak lira."

Data showed Turkey's economy grew 7.4% year-on-year in the third quarter, meeting expectations failing to ease concerns about monetary policy.

For GRAPHIC on emerging market FX performance in 2021, see http://tmsnrt.rs/2egbfVh For GRAPHIC on MSCI emerging index performance in 2021, see https://tmsnrt.rs/2OusNdX

For TOP NEWS across emerging markets

For CENTRAL EUROPE market report, see

For TURKISH market report, see

For RUSSIAN market report, see (Reporting by Shreyashi Sanyal in Bengaluru, editing by Ed Osmond)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
DEUTSCHE BANK AG -1.19% 11.784 Delayed Quote.6.95%
MODERNA, INC. -6.72% 174.07 Delayed Quote.-31.46%
All news about MODERNA, INC.
01:00pPrior COVID infection more protective than vaccination during Delta surge, U.S. study f..
05:18aValneva Shares Suffer as Coronavirus Vaccine Seen Arriving Too Late
01/18US Stocks Slump as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on Financials
01/18US Stocks Start Week Lower as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on ..
01/18Morgan Stanley Adjusts Moderna Price Target to $315 From $313, Maintains Equal Weight R..
01/18Equities Slump Midday After Treasury Yields Touch Two-Year High, Goldman's Earnings Mis..
01/18MIDDAY REPORT : US Stocks Slump After Treasury Yields Touch Two-Year High; Goldman's Earni..
01/18EU regulator finds mRNA COVID-19 shots safe during pregnancy
01/18European Medicines Agency Says mRNA COVID-19 Vaccines Safe In Pregnancy
01/18EU regulator says mRNA COVID-19 shots do not complicate pregnancies
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 520 M - -
Net income 2021 11 079 M - -
Net cash 2021 9 774 M - -
P/E ratio 2021 6,59x
Yield 2021 -
Capitalization 70 577 M 70 577 M -
EV / Sales 2021 3,47x
EV / Sales 2022 2,36x
Nbr of Employees 1 300
Free-Float 90,5%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 19
Last Close Price 174,07 $
Average target price 273,19 $
Spread / Average Target 56,9%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-31.46%75 661
LONZA GROUP AG-15.05%52 427
IQVIA HOLDINGS INC.-14.11%46 293
SEAGEN INC.-15.72%23 824
CELLTRION, INC.-15.66%18 630